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SUMMARY
Objective: To evaluate the prevalence of the urinary excretion of BKV and JCV in HIV-infected patients without neurological 
symptoms. Methods: Urine samples from HIV-infected patients without neurological symptoms were tested for JC virus and BK 
virus by PCR. Samples were screened for the presence of polyomavirus with sets of primers complementary to the early region of 
JCV and BKV genome (AgT). The presence of JC virus or BK virus were confirmed by two other PCR assays using sets of primers 
complementary to the VP1 gene of each virus. Analysis of the data was performed by the Kruskal-Wallis test for numerical data 
and Pearson or Yates for categorical variables. Results: A total of 75 patients were included in the study. The overall prevalence of 
polyomavirus DNA urinary shedding was 67/75 (89.3%). Only BKV DNA was detected in 14/75 (18.7%) urine samples, and only 
JCV DNA was detected in 11/75 (14.7%) samples. Both BKV and JCV DNA were present in 42/75 (56.0%) samples. Conclusion: 
In this study we found high rates of excretion of JCV, BKV, and simultaneous excretion in HIV+ patients. Also these results differ 
from the others available on the literature.
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INTRODUCTION
JC virus (JCV) and BK virus (BKV) are ubiquitous in the human 
population9,29. Serum-prevalence studies have shown that approximately 
70 to 80% of healthy individuals have antibodies against BKV and 
JCV3,11,19,20. In immunocompromised individuals, JCV is associated 
with Progressive Multifocal Leukoencephalopathy (PML), an often fatal 
disease of the central nervous system5,13, and with other neurological 
diseases (granule cell neuronopathy, encephalopathy and meningitis)39. 
In addition, BKV is associated with hemorrhagic cystitis in hematopoietic 
stem cell transplantation (HSCT) recipients and interstitial nephropathy 
in kidney transplant recipients and has recently also been shown to be 
associated with neurologic complications26,41. After primary infection, 
both viruses establish a persistent infection in the kidneys and may be 
excreted in the urine15,22.
The prolonged immunosuppression associated with AIDS contributes 
to the high prevalence of reactivation of these viruses. There are few 
reports on the prevalence of the urinary excretion of JCV and BKV and 
the occurrence of simultaneous excretion in HIV-infected patients7,34. 
Also, BKV and JCV have been gathering attention from scientists 
from different areas of the medicine due to its ability to infect and cause 
disease in patients with different kind of immunosuppression and patients 
treated with monoclonal antibody based therapies30. 
The aim of this study was to evaluate the prevalence of the urinary 
excretion of BKV and JCV in HIV-infected patients without neurological 
symptoms.
METHODS
Patients 
Study and urine samples: Urine samples were collected from 75 
HIV-infected patients without any neurologic symptoms or a history of 
PML who were undergoing regular follow-up at the Outpatient Care Unit 
of the Instituto de Infectologia Emilio Ribas (IIER), São Paulo, Brazil. 
The study was approved by the Ethic Research Committee of the IIER. 
All patients signed an informed consent form.
Sample preparation: BKV and JCV DNA were extracted from 
200 µL urine samples using resin columns (QIAamp® DNA Blood Mini 
Kit, Qiagen, Germany) according to the manufacturer’s instructions.
JCV and BKV DNA detection: All samples were initially screened 
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using PCR according to protocol described by ARTHUR et al.4 and 
standardized by FINK et al.18. This PCR uses primers complementary 
to the early region of the polyomavirus genome that is shared by JCV 
and BKV (T antigen) (Table 1).
The target sequence was amplified in a reaction with a final 
volume of 50 µL containing 10 µL of template, 10X PCR Buffer minus 
Mg, 200 µM dNTPs, 0.5 µM of each primer, 1.5 mM MgCl2, and 
2.5 U/reaction Taq polymerase. 
The reaction was submitted to an amplification of 40 cycles on a 
Perkin Elmer PTC 200 thermocycler as follows: 94 ºC for 1.5 minutes, 
55 ºC for 1.5 minutes and 72 ºC for two minutes. An initial DNA 
denaturation step for 10 minutes and a final extension step for seven 
minutes at 72 ºC were also included. The length of the obtained fragment 
from the amplified samples was 173 bp.
All positive samples for AgT by PCR were submitted to two other 
PCR assays using sets of primers complementary to the genes that express 
the capsid protein, VP1, which differ between JCV and BKV, allowing 
the discrimination between these two polyomavirus.
For JCV, we adopted the protocol described by AGOSTINI et al.1 
with some modifications. The cycle conditions were as follows: 95 ºC 
for five minutes for initial DNA denaturation followed by 50 cycles of 
95 ºC for one minute, 63 ºC for 1.5 minutes, and 72 ºC for one minute 
and then 72 ºC for 10 minutes for a final extension step. The length of 
the obtained fragment from the amplified samples was 215 bp.
For BKV, we adopted the protocol described by KRUMBHOLZ et 
al.31 with some modifications. The cycle conditions were as follows: 94 ºC 
for five minutes for initial DNA denaturation followed by 45 cycles of 
95 ºC for one minute, 63 ºC for 1.5 minutes, and 72 ºC for one minute 
and then 72 ºC for 10 minutes for a final extension step. The length of 
the obtained fragment from the amplified samples was 353 bp.
PCR products were submitted to gel electrophoresis in a 1.5% 
agarose gel stained with ethidium bromide, and visualized after UV 
light exposition.
The original protocol was modified by adding glycerol (57%), an 
adjuvant to improve the amplification of regions rich in G-C12, and Cresol 
red (2.5 µg/µL) to dye the PCR product on the agarose gel24. For all PCR, 
positive and negative controls were added. The negative control consisted 
of the PCR mixture containing water instead of DNA template and to 
avoid contamination, the risks were eliminated by separating work areas 
for mixture preparation and PCR reactions.
The sets of primers used for PCR are presented in Table 1.
Statistical analysis: Analysis of the data was performed by the 
Kruskal-Wallis test with post hoc Dunn’s test for numerical data and 
Pearson or Yates corrected Chi-squared for categorical variables. Values 
of p < 0.05 were considered significant. SPSS 10.0 (IBM, Chicago, IL, 
USA) and GraphPad software (La Jolla, CA, USA) were used.
RESULTS
A total of 75 patients consented to participate in the study. The median 
age was 43 years old (range: 24 to 69 years old). Of these 75 patients, 
49 (65.3%) were men, and 26 (34.7%) were women. The T cell CD4+ 
count was determined for 42/75 patients and ranged from 12 to 1,179 
cells/mm³ (median, 250 cells/mm³).
The overall prevalence of polyomavirus DNA urinary shedding was 
67/75 (89.3%). Only BKV DNA was detected in 14/75 (18.7%) urine 
samples, and only JCV DNA was detected in 11/75 (14.7%) samples. 
Both BKV and JCV DNA were present in 42/75 (56.0%) samples. No 
association was observed between the frequency of JCV and BKV virus 
shedding and the degree of immunodeficiency (p = 0.250). 
Twenty-two women (22/26, 84.6%) and 45 men (45/49, 91.8%) 
presented viral excretion (p = 0.568). A higher percentage of positive 
samples was found among males than among females; however, this 
difference was not statistically significant (Table 2). 
The median and interquartile ranges for age were not statistically 
different among the following groups: JCV (43 ± 12, ranging from 30 
to 54), BKV (39.5 ± 14.5, 24-53), simultaneous excretion (44.5 ± 12.75, 
29-69), positive (43 ± 13, 24-64), negative (44 ± 11.5, 34-54) and total 
(44 ± 11.5, 34-54). These comparisons were made using the Kruskal-
Wallis test (p = 0.203) with post hoc Dunn’s multiple comparison test 
(p > 0.05 for all groups) (Fig. 1).
Table 1 
 Primers used for PCR
Primer Viral Region Sequence Reference
PEP1 AgT AGTCTTTAGGGTCTTCTAC (4)
PEP2 AgT GGTGCCACCTATGGAACAG (4)
JLP-15 VP1 (VJC) ACAGTGTGGCCAGAATTCACTACC (1)
JLP-16 VP1 (VJC) TAAAGCCTCCCCCCCAACAGAAA (1)
BKV1 VP1 (VBK) GAAGTTCTAGAAGTTAAAACTGGG (25, 31)
BKV2 VP1 (VBK) GTGGAAATTACTGCCTTGAATAGG (25, 31)
Table 2
Sex and positivity for polyomavirus BKV and JCV
Sex (n) BKV+ (%) JCV+ (%) Simultaneous excretion Negative p value
Male (49) 9 (18.3) 8 (16.3) 28 (57.0) 4 (8.1)
Female (26) 5 (19.2) 3 (11.5) 14 (53.8) 4 (15.4) 0.768
Total (75) 14 (18.7) 11 (14.7) 42 (56.0) 8 (10.7)
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We stratified the individuals by age and analyzed the number of 
positive cases for BKV and JCV. All subsets included a high number of 
positive individuals, and no significant difference in the proportion of 
positive individuals was observed between subsets (Table 3). 
There was also no statistically significant difference in the medians 
and interquartile ranges of the T cell CD4+ count among all of the 
groups: JCV (250 ± 287.5, ranging from 12 to 550), BKV (339 ± 377, 
160-700), simultaneous excretion (200 ± 416, 46-1,179), positive (220 
± 404.5, 12-1,179), negative (539 ± 600.5, 72-1,016); p = 0.602 by the 
Kruskal-Wallis test with post hoc Dunn’s multiple comparison test (p > 
0.05 for all groups) (Fig. 2). 
DISCUSSION
We observed that 42/75 (56.0%) of the HIV-infected patients were 
excreting both JCV and BKV. There are few reports describing the 
simultaneous excretion of JCV and BKV in this patient population. 
BEHZAD-BEHBAHANI et al., reported a prevalence of simultaneous 
excretion of JCV and BKV of 5.9% in HIV+ patients7. MARKOWITZ 
et al., observed concomitant excretion of JCV and BKV in four out of 
122 (3.3%) HIV-infected patients34. KNOWLES et al., also found low 
prevalence of the excretion of both viruses among HIV-infected patients 
(11/81, 13.2%)28.
In our study the prevalence of BKV in patients who were shedding 
only BKV is similar to that found by MARKOWITZ et al.34, and 
BEHZAD-BEHBAHANI et al.7, ranging from 14% to 20%. However, 
we must consider those patients with simultaneous excretion, which 
makes the frequency of BKV urinary shedding much higher, reaching 
74.6%. Also, a higher rate BKV shedding compared to JCV was reported 
in patients with other immunosuppressive conditions16. 
Moreover, it is known that HIV can transactivate many viruses, among 
which the polyomavirus JC14. There are no data on the dispersion of JC 
virus and BK in our country, our results could reflect a high circulation of 
both viruses in the general population and its reactivation in the presence 
of immunodeficiency frames.
BKV has been shown to have the ability to cause encephalitis26,41 
and hemorrhagic cystitis6 in AIDS patients, as well as urinary system 
diseases in HSCT and kidney transplant recipients. 
PML, formerly a very rare disease10, is now one of the most frequent 
opportunistic diseases among AIDS patients2,8,23, and even after the 
introduction of Highly Active Anti-Retroviral Therapy (HAART), the 
incidence of PML did not decrease like that of other opportunistic 
infections2.
Including the patients who were excreting both viruses, 70% of patients 
of this study were JCV positive. This JCV prevalence is higher than that 
found in other similar studies7,21. The high rate of JCV urinary shedding 
could indicate a high exposure to the virus among this population. 
We did not find any association between JCV and BKV urine excretion 
and the degree of immunodeficiency, as measured by the T CD4+ cell 
count. This finding has also been reported in previous studies. BEHZAD-
BEHBAHANI et al. reported no statistically significant difference in the 
prevalence of JCV and BKV viruria between HIV+ patients with T cell 
CD4+ counts lower and higher than 200 cells/mm³(7), and MATOS et al., 
Fig. 1 - Box plots of the age ranges of patients excreting polyomaviruses. (*) Total included 
positive (JC, BK and simultaneous) and negative samples.
Table 3
Detection of JCV and BKV DNA and simultaneous excretion in HIV+ patients 
stratified by age
Age (n) JC (%) BK (%) Simultaneous(%) Negative (%)
20-29 (3) 0 1 (7.1) 1 (2.4) 0
30-39 (22) 4 (36.4) 5 (35.7) 10 (24) 3 (37.5)
40-49 (31) 5 (45.4) 6 (42.9) 18 (42.6) 3 (37.5)
50-59 (18) 2 (18.2) 2 (14.3) 12 (28.6) 2 (25)
>59 (1) 0 0 1 (2.4) 0
Total (75) 11/75 (14.6) 14/75(18.7) 42/75(56) 8/75(10.6)
p value 
(Pearson c²)
0.888 0.212 0.511 0.949
Fig. 2 - Box plots of the T cell CD4+ counts of patients excreting polyomaviruses. (*) Total 
included positive and negative excretion.
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did not find any association between JCV shedding and the degree of 
immunodeficiency35. MARKOWITZ et al., also did not find any increase 
in the frequency of JCV in HIV-infected patients with different degrees of 
immunodeficiency but did find a correlation between BKV shedding and 
the degree of immunodeficiency: 8% of patients with T cell CD4+ counts 
higher than 500 cells/mm³ shed BKV and 37.5% of patients with T cell 
CD4+ counts lower than 200 cells/mm³ shed BKV34. The same finding 
was reported by KNOWLES et al., 1999, who found BKV DNA in only 
9/40 (22.5%) patients with T cell CD4+ counts higher than 200 cells/mm³ 
and in 21/40 (51.2%) patients with T cell CD4+ counts lower than 200 
cells/mm³ (28). The prevalence of JCV urine shedding was not significantly 
associated with the degree of immunodeficiency.
In the present study, there was no association between JCV and BKV 
shedding and sex, p = 0.768 (Table 2), in contrast to a previous study that 
reported a substantially higher shedding rate among male individuals35.
We observed a slightly higher frequency of the urinary shedding 
of both viruses in older individuals; however, the ages of the 
groups (JCV, BKV, simultaneous excretion and negative) were not 
significantly different (Table 2). This increase has been reported 
for JCV in an immunocompetent population, in which the older the 
population, the higher the frequency of JCV urinary shedding36,42. In an 
immunocompetent population BK virus did not show an increase in the 
frequency of shedding with age36,42.
In immunocompetent populations from Asia and Europe, the 
prevalence of JCV urinary shedding was considerably higher than 
BKV17,27,35,37,40, but in HIV-positive patients, the urinary shedding of 
these viruses has not been well evaluated. SUNDSFJORD et al., found 
a higher number of BKV-positive than JCV-positive urine samples for 
HIV+ patients, but this difference was not significant38. 
Interestingly, we found that the prevalence of urinary shedding of 
BKV in our population was slightly higher than the JCV urinary shedding 
prevalence, but this difference was not statistically significant, probably 
due to the small number of samples after stratification by age and to the 
large number of positive samples in all age groups (p = 0.193). 
Although the data found in this study, the following work has some 
limitations: the HIV, BKV and JCV load were not available. However, other 
studies found no direct association between HIV viral load and excretion of 
polyomavirus. MATOS et al., described that in HIV and JCV co-infected 
individuals, there was no statistical difference between HIV viral load and 
detection of JCV DNA in the urine. Also similar results were found, by 
LEDESMA et al., regarding BK detection and HIV viral load32. 
Also this study does not have a control group. However a recent work 
published by MACHADO et al., 2011, found different rates of JCV and 
BKV urinary shedding in HIV+ children and non-infected children. In this 
study the BKV frequency was significantly higher in HIV infected patients 
in comparison of healthy subjects (54.3% vs. 12.5%)33. However the age 
of the participants of this study is very different from ours, it was not 
possible to compare the two groups. The biological basis and the possible 
viral interactions associated with the high prevalence of co-infection have 
not been well described, also little is known about the shedding dynamics 
of these viruses in these population therefore, further studies should be 
done. In summary, in our study, we found high rates of urinary shedding 
of JCV (70.7%) and BKV (74.7%) in this HIV-infected patients group. In 
addition, we also found high rates of the simultaneous excretion of JCV and 
BKV (56%) in HIV+ patients, a result that has not been reported before. 
RESUMO
Alta prevalência de excreção simultânea de poliomavírus JC e BK 
na urina de pacientes HIV+ sem sintomas neurológicos em São 
Paulo, Brasil
Objetivo: Avaliar a prevalência de excreção urinaria de vírus JC 
(VJC) e vírus BK (VBK) em pacientes HIV+ sem sintomas neurológicos. 
Métodos: Amostras de urina de pacientes HIV+ sem sintomas neurológicos 
foram testados para a presença de VJC e VBK através da técnica de PCR. As 
amostras foram triadas para a presença de poliomavírus com par de primers 
complementares a região precoce do genoma do VBK e do VJC (AgT). A 
presença foi confirmada através de dois outros ensaios de PCR dirigidos 
a região do gene VP1 de ambos os vírus. A análise estatística foi realizada 
com auxílio do teste de Kruskal-Wallis para dados numéricos e Pearson 
ou Yater para variáveis categóricas. Resultados: Ao todo foram inclusos 
no estudo 75 pacientes. A prevalência geral de excreção de poliomavírus 
na urina foi de 67/75 (89,3%). O DNA do vírus VBK foi detectado em 
14/75 (18,7%) das amostras de urina, e o DNA do VJC foi detectado em 
11/75 (14,7%) das amostras testadas. Ambos os vírus estavam presentes 
simultaneamente em 42/75 (56%) das amostras de urina. Conclusão: 
Encontramos, no presente estudo, uma alta taxa de excreção de VJC, VBK 
e excreção simultânea em pacientes HIV+. Ainda, esses resultados diferem 
de outros disponíveis na literatura. 
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